1
Tarran Jones
Goldstein Neil I, Giorgio Nicholas A, Jones Steven Tarran, Saldanha Jose William: Antibody and antibody fragments for inhibiting the growth of tumors. Imclone Systems, April 1, 1998: EP0831880-A1

Chimerized and humanized versions of anti EGF receptor antibody 225 and fragments thereof for treatment of tumors.


2
Cabilly Shmuel, Holmes William Evans, Wetzel Ronald Burnell, Heyneker Herbert Louis, Riggs Arthur Dale: Recombinant immunoglobulin preparations, methods for their preparation, dna sequences, expression vectors and recombinant host cells therefor.. Genentech, Hope City, November 14, 1984: EP0125023-A1 (379 worldwide citation)

Recombinant DNA techniques are used to produce both immunoglobulins which are analogous to those normally found in vertebrate systems and to take advantage of these gene modification techniques to construct chimeric or other modified forms.


3
Houghton Michael, Choo Qui Lim, Kuo George: Nanbv diagnostics and vaccines.. Chiron, September 19, 1990: EP0388232-A1 (204 worldwide citation)

A new virus, Hepatitis C virus (HCV), which has proven to be the major etiologic agent of blood-borne NANBH, was discovered by Applicant. The initial work on this virus, which includes a partial genomic sequence of the prototype HCV isolate, is described in EPO Pub. No. 318,216, and PCT Pub. No. WO/ ...


4
Mcphee Fiona, Campbell Jeffrey Allen, Li Wenying, D Andrea Stanley, Zheng Zhizhen Barbara, Good Andrew Charles, Carini David J, Johnson Barry L, Scola Paul Michael: Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus. Bristol Myers Squibb Company, Mcphee Fiona, Campbell Jeffrey Allen, Li Wenying, D Andrea Stanley, Zheng Zhizhen Barbara, Good Andrew Charles, Carini David J, Johnson Barry L, Scola Paul Michael, VOLLES Warren K, November 4, 2004: WO/2004/094452 (132 worldwide citation)

Macrocyclic isoquinoline are disclosed having the general formula: A compound of formula 1: wherein R1 to R9, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.


5

6
Szelke Michael: Enzyme inhibitors.. Szelke Michael, Jones David Michael, Hallet Allen, Atrash Butrus, March 28, 1984: EP0104041-A1 (124 worldwide citation)

Renin inhibitory polypeptide analogues derived from the natural N-terminal substrate sequence by replacing the amino acid at position 10 with statine or a residue related to it.


7
Wallach David, Engelmann Hartmut, Aderka Dan, Novick Daniela, Rubinstein Menachem: Tumor necrosis factor binding protein ii, its purification and antibodies thereto.. Yeda Res & Dev, November 22, 1990: EP0398327-A1 (106 worldwide citation)

Tumor Necrosis Factor (TNF) Binding Protein is isolated and substantially purified. It has the ability to inhibit the cytotoxic effect of TNF and/or to maintain its prolonged beneficial effects. TNF Binding Protein II and salts, functional derivatives, precursors and active fractions thereof can be ...


8
Brockhaus Manfred Dr, Dembic Zlatko Dr, Gentz Reiner Dr, Lesslauer Werner Dr, Loetscher Hansruedi Dr, Schlaeger Ernst Juergen Dr: Tnf-binding proteins.. Hoffmann La Roche, March 20, 1991: EP0417563-A2 (99 worldwide citation)

The present invention relates to non-soluble proteins and to soluble or non-soluble fragments thereof, which bind TNF, in homogeneous form, and to the physiologically tolerated salts thereof, especially those proteins with a molecular weight of about 55 or 75 kD (non-reducing SDS-PAGE conditions), t ...


9
Fung Sek Chung, Moyle Matthew, Lu Mason, Yan Changning, Singh Sanjaya, Huang Dan: Novel anti-il 13 antibodies and uses thereof. Tanox, Fung Sek Chung, Moyle Matthew, Lu Mason, Yan Changning, Singh Sanjaya, Huang Dan, LILJESTRAND Cheryl A, July 14, 2005: WO/2005/062967 (84 worldwide citation)

The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the us ...


10
Marguerie de Rotrou Gerard Arm: Peptide derivatives and their therapeutical use.. Inst Nat Sante Rech Med, Lafon Labor, July 27, 1988: EP0275748-A1 (84 worldwide citation)

Peptide derivatives of formula X-X-Gly-Asp-X-X (I) in which X denotes hydrogen, an N-protective group, an amino acid residue or an N-protected amino acid residue, X denotes an L-Arg or D-Arg, L-Orn or D-Orn, N-aminocarbonyl-L-Orn or N-aminocarbonyl-D-Orn, or L-Lys or D-Lys residue, X denotes an L-Tr ...